# Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors

> **NCT02876224** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 51 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab
- **DRUG:** Cobimetinib

## Key facts

- **NCT ID:** NCT02876224
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-30
- **Primary completion:** 2019-06-25
- **Final completion:** 2019-06-25
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2019-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02876224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02876224, "Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02876224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*